Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao(Zhejiang University), Yongxian Hu(University of Akron), Jimin Shi(Zhejiang University), Mohamad Mohty(Sorbonne Université), Didier Blaise(Institut Paoli-Calmettes), Siguo Hao(XinHua Hospital), Alex H. Chang(University of Wisconsin Carbone Cancer Center), Mingfeng Zhao(Nankai University), Elaine Tan Su Yin(Zhejiang University), Xianmin Song(Shanghai Stomatological Hospital), Yamin Tan(Zhejiang University), Yanmin Zhao(Shanghai Jiao Tong University), Arnon Nagler(Sheba Medical Center), Jieping Wei(Zhejiang University), Jianmin Yang(Canadian Food Inspection Agency), Lei Xiao(Shanghai Cell Therapy Research Institute), Yi Luo(Zhejiang Lab), Hongmei Jing(Peking University), Xin Li(Tianjin Medical University General Hospital), Jing Chen(Zhejiang Institute of Special Equipment Inspection), Yuhua Li(Zhujiang Hospital), Ping Li(Tongji Hospital), Qing Zhang(Beijing Hospital of Traditional Chinese Medicine), Tao Wang(Second Military Medical University), He Huang(Peking University), Wenjun Wu(First Affiliated Hospital Zhejiang University), Yunxiong Wei(Tianjin First Center Hospital), Jian Yu(Zhejiang University), Guoqing Wei(Zhejiang University), Qu Cui(Capital Medical University), Xiaoyu Lai(Zhejiang University), Aibin Liang(Tongji Hospital), Jing Huang(Nanchang University)
Cited by 82
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534